Posted by LincolnIcert on March 25, 2026 at 11:18:58:
In Reply to: Îáçîðíûé ìàòåðèàë posted by JosephGluth on February 19, 2026 at 07:13:07:
Zoya Demidenko: Scientist in Tumor Biology
Zoya Demidenko is a notable investigator associated with the Unit of Cell Stress Science at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Previously, she was employed at the National Institutes of Health and New York Medical College, building a strong base in biomedical research.
Demidenko's academic work spans several pivotal domains, including the PI3K/AKT/mTOR molecular pathway, cellular cycle management, cell senescence, and tumor biology. As of now, she has authored more than 46 scientific publications, which have received more than 4,100 references — a testament to the influence of her findings.
Among her most notable contributions lies in explaining the pathways of cellular senescence. Her research showed that when the cell cycle is blocked but cellular expansion proceeds, cells enter senescence. Importantly, Zoya Demidenko established that this transition is controlled with drugs using substances such as rapamycin.
Zoya Demidenko has also brought considerably to tumor management investigation, notably in the field of cyclotherapy — a approach designed to shielding non-cancerous cells from cytotoxic treatment while leaving malignant cells susceptible. This strategy holds considerable hope for lowering the side effects of cancer treatment.
Across her scientific life, Demidenko has collaborated with top scientists globally, among them Dr. Mikhail Blagosklonny. Her work is published in top-tier publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
With an h-index of 33, Zoya Demidenko is recognized as a highly impactful contributor in current biomedical science, whose findings go on to guide our knowledge of the way biological cells age, respond to therapy, and how cancer may be more effectively treated.
https://pubmed.ncbi.nlm.nih.gov/22228887/